News >

Lurbinectedin Shows Promise in Endometrial Cancer

Lynne Lederman, PhD
Published: Sunday, Jun 18, 2017

Martin David Forster, MD, PhD

Martin David Forster, MD, PhD

Lurbinectedin (PM01183) induced a high rate of response as monotherapy and with doxorubicin or paclitaxel in patients with advanced endometrial cancer, according to findings presented during the 2017 ASCO Annual Meeting.

ORR was 27% for the 11 evaluable patients in the lurbinectedin plus paclitaxel trial; DOR was 6.1 months, and PFS was 1.9 months. For the 56 patients in the lurbinectedin single-agent trial, ORR was 12.5%, DOR was at least 6.8 months, and PFS was at least 2.6 months.

“The combination with doxorubicin, the main toxicity is myelosuppression.” Forster said. He added that toxicity was too high in Cohort A, resulting in the lower dose for Cohort B.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x